Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...